Amphiphysin-IgG自身免疫性神经病:可识别的临床病理综合征
孤立Amphiphysin-IgG患者免疫治疗应答率44%,显著高于CRMP5-IgG多神经病患者(16%),且神经病常提示乳腺癌诊断(76%)。
要点
- Amphiphysin-IgG神经病常伴疼痛、乳腺癌和中枢神经系统受累,神经病可提示乳腺癌早期诊断。
- 孤立Amphiphysin-IgG患者免疫治疗应答率44%,优于CRMP5-IgG多神经病(16%)。
- 合并CRMP5-IgG或ANNA1-IgG者免疫治疗应答率仅11%。
核心结论
- Amphiphysin-IgG自身免疫性神经病具有可识别的表型,常对免疫治疗有反应,并可提示乳腺癌的早期诊断。
主要发现
- 33例(60%)患者有神经病,其中21例为孤立Amphiphysin-IgG,12例合并其他自身抗体(ANNA1-IgG 8例,CRMP5-IgG 2例,两者均合并2例)。
- 孤立Amphiphysin-IgG自身免疫中的神经病包括多神经根神经病(62%)、弥漫性感觉神经元病(35%)和面神经病伴胃轻瘫(3%)。
- 疼痛(80%)、乳腺癌(63%)和中枢神经系统受累(57%)常见共存,神经病常促使乳腺癌诊断(76%)。
- 神经活检显示轴索丢失(6/6)、神经束膜下水肿(4/6)和CD4主导的炎症(2/6)。
- 末次随访中位mRS评分为3.5;58%的患者对免疫治疗有反应。
关键数值与推荐
- 免疫治疗反应定义为随访时改良Rankin量表(mRS)改善≥1分。
- 孤立Amphiphysin-IgG患者免疫治疗应答率44%(21例中),CRMP5-IgG多神经病患者为16%(45例中),p=0.028,OR=4.2,95%CI 1.1-15.5。
临床怎么用
- 对疑似自身免疫性神经病患者应检测Amphiphysin-IgG,尤其伴疼痛、乳腺癌或中枢神经系统症状时。
- Amphiphysin-IgG阳性神经病常对免疫治疗有反应,孤立阳性者应答率更高,应积极考虑免疫治疗。
- Amphiphysin-IgG神经病可提示乳腺癌早期诊断,建议进行乳腺癌筛查。
局限性
- 未提供对照组的详细基线特征,免疫治疗反应评估可能受混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define the clinicopathologic features of amphiphysin-immunoglobulin G (IgG)-mediated neuropathy. METHODS: Patients examined at our institution from January 1, 1995, to September 30, 2018, with amphiphysin-IgG by indirect immunofluorescence and Western blot, were reviewed. Their phenotypes were compared to cases of coexisting collapsin response-mediator protein-5 (CRMP5)-IgG or anti-neuronal nuclear antibody type 1 (ANNA1-IgG) and CRMP5-IgG autoimmunity. Improvement in modified Rankin Scale (mRS) (≥1) on follow-up was considered a favorable outcome. Amphiphysin RNA expression was assessed in healthy nerves. RESULTS: Fifty-three amphiphysin-IgG-positive cases were identified. Of 33 (60%) patients with neuropathy, 21 had amphiphysin-IgG alone, and 12 had coexisting autoantibodies (ANNA1-IgG, n = 8; CRMP5-IgG, n = 2; ANNA1-IgG and CRMP5-IgG, n = 2). The neuropathies in isolated amphiphysin-IgG autoimmunity included polyradiculoneuropathy (62%), diffuse sensory neuronopathy (35%), and facial neuropathy with gastroparesis (3%). Among these, pain (80%), breast cancer (63%), and CNS (57%) involvements commonly coexisted, and neuropathy frequently prompted breast cancer diagnosis (76%). Stiff-person spectrum disorder was the most common CNS accompaniment (45%). Nerve biopsies showed axonal loss (n = 6/6), subperineurial edema (n = 4/6), and CD4 predominant inflammation (n = 2/6). Median mRS score at last follow-up was 3.5; 58% of patients were immunotherapy-responsive. Patients with amphiphysin-IgG alone had more favorable immunotherapy response than patients with CRMP5-IgG polyneuropathy (n = 45) (44% vs 16%, p = 0.028, odds ratio 4.2, 95% confidence interval 1.1 to 15.5). Only 1/9 (11%) patients with amphiphysin-IgG with coexisting CRMP5-IgG or ANNA1-IgG had immunotherapy response. RNA amphiphysin expression occurred at low levels in nerve. CONCLUSION: Amphiphysin-IgG autoimmune neuropathy has a recognizable phenotype, is frequently immune responsive, and can prompt early diagnosis of breast cancer.
引用
- Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019. PMID: 31624089. doi:10.1212/WNL.0000000000008472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。